Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 364

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 3
Chunk 364
---
 filed a notice of appeal of the court’s decision granting the director defendants’ motion to dismiss. The appeal
remains pending.

On June 21, 2024, the Company
filed suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the
Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gümrükcüand others
deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger
agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment,
equitable fraud, unjust enrichment, and civil conspiracy and seeks, inter alia, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants’ motion under advisement.

Renovaro, Inc. (“Renovaro”)
commenced an action against Predictive Oncology, Inc. (“POAI”) in the Delaware Court of Chancery claiming that POAI breached
a “definitive” January 2025 Letter Agreement pursuant to which Renovaro was going to acquire POAI. As a result of its breach,
POAI made that acquisition impossible and dramatically devalued the share price of stock Renovaro had already acquired as well as the
value of the company it was contractually entitled to acquire. Renovaro sought specific perfo1mance or, in the alternative, money damages.
The parties have exchanged paper discovery and noticed depositions. The action has been held in abeyance while the parties attempt to
negotiate a settlement.

Item 4. Mine Safety Disclosures.

Not applicable.

54

PART II

Item 5. Market for Registrant’s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities 

Market Information and Holders of our Common Stock

Our Common Stock trades on the
Nasdaq Capital Market under the symbol “RENB”.

As of September 26, 2025, the
Company had 231,802,470 shares of Common Stock issued and approximately 233 stockholders of record. The actual number of stockholders
is greater than